annb0t
Top 20
Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University of Utah. A poster presentation showed that paxalisib is active in vitro and in vivo against a range of preclinical models of metastatic melanoma, the most aggressive form of skin cancer. The data suggested substantial activity for paxalisib as monotherapy and greater activity in combination with MEK and BRAF inhibitors, commonly used two clas...
>>> Read more: Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models
>>> Read more: Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models
